Noxopharm【NOX】銘柄情報

Noxopharm Limited (NOX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.092

( - )

買値

0.092

売値

0.10

出来高

0.00

0.00 日の範囲 0.00

0.043 52 週間の範囲 0.135

時価総額

26.886M

前日終値

0.092

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 228,258

発行済株式数

292,237,950

配当利回り

PER

-4.52

1 株当たり利益 (EPS)

-0.02

歳入

3.4M

純利益

-5.49M

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatm... Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.noxopharm.com

本社

Glenhaven, Australia

設立

2026

Noxopharm Limited is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker NOX. The last closing price for Noxopharm was AUD0.09. Over the last year, Noxopharm shares have traded in a share price range of AUD 0.043 to AUD 0.135.

Noxopharm currently has 292,237,950 shares in issue. The market capitalisation of Noxopharm is AUD26.89 million. Noxopharm has a price to earnings ratio (PE ratio) of -4.52.

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to...

Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its Phase 1 CEP-2 sarcoma trial is underway with a first...

Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

Exclusive deal for cutting-edge RNA technology in drug discovery and vaccines Australian clinical-stage drug development company Noxopharm...

Noxopharm Announces DARRT-2 Clinical Trial in U.S.

Experimental Immunotherapy Cancer Treatment Enters Phase 2 Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced...

ノクソファームの前臨床データがCOVID-19の治療におけるイドロノキシルの抗炎症作用をさらに裏付ける

（ビジネスワイヤ） -- オーストラリアの臨床段階医薬品開発企業であるノクソファーム（ASX:NOX）は、治験薬の抗がん剤でビヨンダの有効成分となっているイ...

Les données précliniques de Noxopharm confirment le rôle anti-inflammatoire de l’idronoxil dans le cadre du traitement de la COVID-19

La société australienne de développement de médicaments de stade clinique, Noxopharm (ASX : NOX) a publié des données précliniques qui viennent...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.001	-1.0752688172	0.093	0.11	0.085	332048	0.0940912	DE
4	0.017	22.6666666667	0.075	0.11	0.071	241344	0.08798184	DE
12	0.032	53.3333333333	0.06	0.11	0.051	237443	0.08054169	DE
26	-0.002	-2.12765957447	0.094	0.11	0.051	203754	0.07647621	DE
52	0.04	76.9230769231	0.052	0.135	0.043	195283	0.08426361	DE
156	0.047	104.444444444	0.045	0.165	0.033	267460	0.08920272	DE
260	-0.578	-86.2686567164	0.67	0.705	0.033	296403	0.17466052	DE